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Abstract 
Identification of drug-target interactions (DTIs) plays a key role in drug discovery. The high 
cost and labor-intensive nature of in vitro and in vivo experiments have highlighted the 
importance of in silico-based DTI prediction approaches. In several computational models, 
conventional protein descriptors are shown to be not informative enough to predict accurate 
DTIs. Thus, in this study, we employ a convolutional neural network (CNN) on raw protein 
sequences to capture local residue patterns participating in DTIs. With CNN on protein 
sequences, our model performs better than previous protein descriptor-based models. In 
addition, our model performs better than the previous deep learning model for massive 
prediction of DTIs. By examining the pooled convolution results, we found that our model 
can detect binding sites of proteins for DTIs. In conclusion, our prediction model for 
detecting local residue patterns of target proteins successfully enriches the protein features of 
a raw protein sequence, yielding better prediction results than previous approaches. 
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Fig 1 . Overview of our model. First, we collected training DTI dataset from various 
databases (DrugBank, KEGG, IUPHAR). Second, we constructed the neural network model 
using convolution, which is able to capture local residue patterns that can help the DTIs. 
Third, we optimized the hyperparameters with an external validation dataset that we 
constructed. Finally, we predicted DTIs from bioassays (independent test dataset) and 
evaluated the performance of our model. The number (#) of each compounds, proteins and 
DTIs are summarized in each step. 
 
Introduction 
The identification of drug-target interactions (DTIs) plays a key role in the early stage of drug 
discovery. Thus, drug developers screen for compounds that interact with specified targets 
with biological activities of interest. However, the identification of DTIs in large-scale 
chemical or biological experiments usually takes 2~3 years of experiments, with high 
4 
 
associated costs [1] Therefore, with the accumulation of drugs, targets, and interaction data, 
various computational methods have been developed for the prediction of possible DTIs to 
aid in drug discovery. 
Among computational approaches, several similarity-based methods were initially studied, in 
which it was assumed that drugs bind to proteins similar to known targets and vice versa. One 
of the early methods is that of Yamanashi et al., which used a kernel regression method to use 
information on known drug interactions as the input to identify new DTIs, combining a 
chemical space and genomic spaces into a pharmacological space [2]. To overcome the 
requirement of the bipartite model for massive computational power, Beakley et al. developed 
the local bipartite model, which trains the interaction model locally but not globally. In 
addition to substantially reducing the computational complexity, this model exhibited higher 
performance than the previous model [3]. As another approach to DTI prediction models, 
matrix factorization methods are recruited to predict DTIs, which approximate multiplying 
two latent matrices representing the compound and target protein to an interaction matrix and 
similarity score matrix [4, 5]. In this work, regularized matrix factorization methods 
successfully learn the manifold lying under DTIs, giving the highest performance among 
previous DTI prediction methods. However, similarity-based methods are not commonly 
used at present to predict DTIs, as researchers have found that similarity-based methods work 
well for DTIs within specific protein classes but not for other classes [6]. In addition, some 
proteins do not show strong sequence similarity with proteins sharing an identical interacting 
compound [7]. 
Thus, feature-based models that predict DTI features of drugs and targets have been studied 
[8-10]. For the feature-based DTI prediction models, a fingerprint is the most commonly used 
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descriptor of the substructure of the drug [11]. With the drug fingerprint, the drug is 
transformed into a binary vector whose index value represents the existence of the 
substructure in the drug. For proteins, the composition, transition, and distribution (CTD) 
descriptors are conventionally used as computational representations [12]. Unfortunately, 
feature-based models that use the protein descriptor and drug fingerprint showed worse 
performance than the previous conventional quantitative structure-activity relationship 
(QSAR) models [8]. To improve the performance of the feature-based models, many 
approaches have been developed, such as the use of interactome networks [13] and minwise 
hashing [14]. Although various protein and chemical descriptors have been introduced, 
feature-based models do not show sufficiently good predictive performance [15]. For 
conventional machine learning models, features must be built to be readable by modeling 
from original raw forms, such as SMILES and amino acid sequences. During transformation, 
rich information, such as local residue patterns or relationships, is lost. In addition, it is hard 
to recover lost information using traditional machine learning models. 
In recent years, many deep learning approaches have recently been developed and recruited 
for omic data processing [16] as well as drug discovery [17], and these approaches seem to be 
able to overcome limitations. For example, Wen et al. used the deep belief network (DBN) 
[18], with features such as the composition of amino acids, dipeptides, and tripeptides for 
proteins, and extended-connectivity fingerprint (ECFP) [19] for drugs [6]. They also 
discussed how deep-learning-based latent representations, which are nonlinear combinations 
of original features, can overcome the limitations of traditional descriptors by showing the 
performance in each layer. In another study [20], the researchers employed stacked 
autoencoder (SAE) with sparsity constraints to abstract original features into a latent 
representation with a small dimension. With latent representation, they trained a support 
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vector machine (SVM), which performed better than previous methods, including feature- 
and similarity-based methods. In another study by Tian et al. [21], domain binary vectors 
were employed to represent the existence of domains used to describe proteins. 
One way to reduce the loss of information of features is to process raw sequences and 
simplified molecular-input line entry system (SMILES) as their forms. In a paper by Öztürk 
et al., DeepDTA was used to represent raw sequences and SMILES as one-hot vectors or 
labels [22]. With a convolutional neural network (CNN), they extracted local residue patterns 
to predict the binding affinity between drugs and targets. As a result, their model exhibited 
better performance on a kinase family bioassay dataset [23] than the previous model, 
kronRLS [24]. In their model, the Smith-Waterman similarity (SW) [25] score performed 
better than CNN on protein sequences, while CNN performed better than SIMCOMP on 
SMILES [26]. However, their CNN method had a bias for the maximum length of proteins 
because they stacked the CNN to yield local residue patterns. We can still recruit CNN to 
extract local residue patterns for DTI without losing generality and rich information regarding 
protein residues and without a bias for the maximum length of proteins.  
To overcome the aforementioned problems, here, we introduce a deep learning model that 
predicts massive-scale DTIs using raw protein sequences not only for various target protein 
classes but also for diverse protein lengths. The overall pipeline of our model is depicted in 
Fig 1. We adopted convolution filters on the entire sequence of a protein to capture local 
residue patterns, which are the main protein residues participating in DTIs. By pooling the 
maximum results of CNN, we can determine how given protein sequences match local 
residue patterns participating in DTIs. Using these data as input variables of higher layers, 
our model constructs abstracts and organizes features for proteins. Finally, our model 
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concatenates protein features with drug features, which come from fingerprints through the 
fully connected layer and predict the probability of DTIs via higher fully connected layers. 
We trained our model with large-scale DTI information integrated from various DTI 
databases, such as DrugBank, International Union of Basic and Clinical Pharmacology 
(IUPHAR), and Kyoto Encyclopedia of Genes and Genomes (KEGG), and we optimized the 
model with DTIs from MATADOR and negative interactions predicted from Liu et al. [27]. 
With the optimized model, we predicted DTIs from bioassays such as PubChem BioAssays 
and KinaseSARfari to estimate the performance of our model. As a result, our model exhibits 
better performance than a previous model that uses CTD and SW scores. 
Results and Discussion 
 
 
Fig 2. Performance curves for optimized models of protein descriptors. The AUPR and 
AUC of the convolution, CTD, and similarity descriptors are shown in panels A and B, 
respectively. 
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Performances of the validation dataset and selected hyperparameters 
As a normal step of hyperparameter setting, we first tuned the learning rate of the weight 
update to 0.0001. After the learning rate was fixed, we benchmarked the sizes and number of 
windows, hidden layers of the drug features, and the concatenating layers with area under 
precision-recall (AUPR). Finally, we selected the hyperparameters of the modelwith the 
unseen validation dataset, yielding an AUPR of 0.832, as shown in Fig 2. The AUPR value of 
our model was less than the AUPR of the similarity descriptor; however, that does not mean 
that our method has lower prediction performance than the similarity method because the size 
of the validation dataset is too small to evaluate the general performance. In the same 
manner, we built and optimized models that use other protein descriptors with the same 
activation function, learning rate, and decay rate. 
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Fig 3. Performance measures (Sen, Spe, Pre, Acc, F1) for all of the independent datasets 
of the PubChem dataset. (A) All queried PubChem datasets. (B) PubChem dataset whose 
compounds are not in the training dataset. (C) PubChem dataset whose targets are not in the 
training dataset. (D) PubChem dataset whose compounds and targets are not in the training 
dataset. Our convolution model shows better performances for all datasets in terms of 
accuracy and F1 score. 
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Comparison of performance with other protein descriptors 
After the hyperparameters were tuned, we compared the performance based on the 
independent test datasets with the different protein descriptors, the CTD descriptor (which is 
usually used in the conventional chemo-genomic model) [12], normalized SW score [25], and 
our convolution method. The results showed that our model exhibited better performance 
than the other protein descriptors for all the datasets as shown in Fig 3. With the threshold 
selected by equal error rate (EER) [28], our model performed equally well with both the 
PubChem and KinaseSARfari datasets, indicating that our model has general application 
power. Our convolution method gave the highest accuracy score and F1 score for the 
PubChem dataset (Fig 3A) [29] and its subsets (Fig 3B-D) and a slightly lower F1 score for 
the KinaseSARfari dataset  [30]. The CTD descriptor gave the lowest score for any dataset 
and any metric, which implies that CTD is less informative and less enriched than the other 
descriptors. Here, we also observed that the model performance using a similarity descriptor 
for the KinaseSARfari dataset was similar to that of the proposed model. We can interpret 
this result as the similarity descriptor acts as an informative feature as a local residue pattern 
at the domain level, not the whole protein complex.  
 
Fig 4. Comparison of performances between our model and that of Wen et al. 
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Performance comparison with a previous model 
In addition to the comparison between convolution in our model and other protein 
descriptors, we compared our model and a previous model. The previous model selected for 
comparison was built by Wen et al. [6]. Other studies have found it difficult to compare 
performance because their purposes and datasets are different from those of our model. We 
used their optimized shape hyperparameters and descriptors to represent the DTI, but we used 
a lower fine-tuning learning rate because the model cannot learn with a high fine-tuning 
learning rate of 0.1. We decreased the fine-tuning learning rate to 0.01 and executed fine-
tuning until the validation error converged. After the pretraining and fine-tuning stages, we 
evaluated the PubChem dataset and compared the result with our model. In the comparison, 
our model performed better than the previous model, as shown in Fig 4. The previous model 
was built with deep belief network (DBN) [18], which is a stack of Restricted Boltzmann 
machine. 
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Fig 5. Statistical test for binding region detection. We executed a right-tailed t-test for the 
number of covering binding sites from the convolution results with a null distribution, which 
was constructed from the randomly generated convolution results in the sc-PDB database 
consisting of 7179. Because each sc-PDB test has many windows, we selected the most 
significant p-value adjusted by the Benjamini-Hochberg procedure and examined whether 
they were significant at levels of 1%, 5% and 10%. As a result, 6%, 15% and 22.5% of sc-
PDB entries were significantly enriched, respectively. 
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Fig 6. Visualization of binding sites. (A) Binding sites of the cellular tumor antigen protein 
(P04637, P53_HUMAN). (B) Binding sites of the Estrogen receptor protein (P03372, 
ESR1_HUMAN). The blurred ligand can differ by sc-PDB entry. Binding sites from sc-PDB 
entries are colored red. Pooled convolution results are shown as transparent blue boxes that 
exactly cover the binding residues. 
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Detection of the binding site by CNN on the sequence 
Because we pooled the maximum convolution results by each filter for each window, the 
pooled results could highlight regions of matches with local residue patterns. Although we 
cannot measure exactly how those values affect the DTI prediction results, the pooled 
maximum convolution result will affect the prediction performance by going through higher 
fully connected layers. Therefore, if our model is capable of capturing local residue patterns, 
it would give high values to important regions of protein, such as actual binding sites. 
Examining and validating the convolution results from the intermediate layer showed that our 
model could capture local residue patterns that participate in DTIs. The sc-PDB database 
provides atom-level descriptions of proteins, ligands, and binding sites from complex 
structures [31]. By parsing binding site annotations, we can query binding sites between 
protein domains and pharmacological ligands for 7179 entries of Vertebrata. From the 
queried binding sites and pooled maximum convolution results, we statistically test our 
assumption that the pooled maximum convolution results cover the important regions, 
including binding sites. Each window has 128 pooled convolution results, which shows bias 
in covering some regions. Thus, we randomly generated 128 convolution results 10,000 times 
for each sc-PDB entry and counted how many of those random results covered each amino 
acid in binding sites, which constructed normal distributions. For each normal distribution 
constructed by the randomly generated convolution results, considered as a null hypothesis, 
we executed a right-tailed t-test with the number from the convolution results of our model 
for each window. Because we did not know which window detects the binding site, we took 
the most significant p-value (minimum p-value adjusted by the Benjamini-Hochberg 
procedure [32]).. We summarize the results of binding site detection from the most 
significant p-value among windows by significant level cutoff in Fig 5. In addition, we 
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examined scPDB entries with the most significant p-values for diverse window sizes. As 
expected, the convolution results gave high values when binding sites were included. For 
example, cellular tumor antigen p53 (P04637, P53_HUMAN) has many sc-PDB entries with 
many pharmacological ligands. In Fig 6A, annotated binding sites from many sc-PDB entries 
with P53_HUMAN are colored red for each sc-PDB entry. For the annotated region, some 
pooled results from the convolution layers exactly cover the binding sites with high ranks 
among filters in a window, which must affect the prediction scores. In addition, these 
convolution results cover more complicated sites. For the protein Estrogen receptor (P03372, 
ESR1_HUMAN), which is a nuclear hormone receptor, 4 binding sites are covered with 
convolution results from the model with high rank among filters in windows, as shown in Fig 
6B. Although we only studied binding sites, we assume that our method could enrich other 
important regions. 
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Fig 7. t-SNE results with protein features from the fully connected layer beyond 
the global max-pooling layer of the convolution result.Each color corresponds to a 
protein class. The visualization result shows that our model is able to roughly 
discriminate protein classes by capturing local residue patterns. 
 
t-SNE visualization of proteins 
From the results shown in Fig 6, we can confirm that our model can capture the local residue 
patterns of proteins that participate in DTIs. Thus, to examine further characteristics of the 
captured protein local residue patterns, we visualized the protein features from the fully 
connected layer after the global max-pooling of convolution results. We visualized 1,527 
proteins used in the training dataset categorized in various protein classes. Specifically, we 
visualized 257 GPCRs, 44 nuclear receptors, 304 ion channel receptors, 604 kinases, and 318 
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protease. For the visualization, we conducted t-distributed stochastic neighbor embedding (t-
SNE) for dimension reduction and visualization [33]. t-SNE can map high-dimensional 
features to low-dimensional ones, such as 2-dimensional features, minimizing information 
loss during dimension reduction. Surprisingly, although our model is not intended to identify 
protein classes, it can roughly discriminate protein classes from the intermediate protein 
layer, as shown in Fig 7. 
Materials and Methods 
Building dataset 
To build the training dataset, we obtained known DTIs from three databases: DrugBank [34], 
KEGG [35], and IUPHAR [36]. To remove duplicate DTIs among the three databases, we 
unified the identifiers of the compounds and the proteins. For the drugs, we standardized the 
identifiers of the compounds in the DrugBank and KEGG databases with the InChI 
descriptor. For the proteins, we unified the identifiers of the proteins as UniProtKB/Swiss-
Prot accessions [37]. Among the collected DTIs, we selectively removed proteins of 
Prokaryota and single-cell Eukaryota, retaining only proteins of Vertebrata. Finally, 11,950 
compounds, 3,675 proteins, and 32,568 DTIs were obtained in total. Because all collected 
DTIs are regarded as positive samples for training and negative DTIs are not defined in the 
databases above, a random negative DTI dataset is inevitably generated. To reduce bias from 
the random generation of negative DTIs, we built ten sets of negative DTIs exclusively from 
the positive dataset.  
To optimize our model with the most adequate hyperparameters, we constructed an external 
validation dataset that had not seen DTIs in the training phase. We collected positive DTIs 
from the MATADOR database [38], including ‘DIRECT’ protein annotations, and all the 
18 
 
DTIs observed in the training dataset were excluded. To build a credible negative dataset, we 
obtained negative DTIs via the method of Liu et al. This method selects candidate negative 
DTIs with low similarity to known positive DTIs [27]. From the obtained negative dataset, 
we balanced the negative dataset with the positive dataset, using a negative score (>0.95). As 
a result, 370 positive DTIs and 507 negative DTIs were queried for the external validation 
set.  
For the evaluation of our model, we built two independent test datasets from the PubChem 
BioAssay database [29] (Wang, et al., 2017) and ChEMBL KinaseSARfari [30]; these 
datasets consisted of results from experimental assays. To obtain positive DTIs from 
PubChem, we collected ‘Active’ DTIs from the assays with the dissociation constant (Kd < 
10μm)[39]. Because we sought to predict whether a drug binds to a protein, among the many 
types of assays (Potency, IC50, AC50, EC50, Kd, Ki), the evaluation of the dissociation constant 
(Kd) was the most appropriate assay for obtaining positive samples. For the negative samples, 
we took the samples annotated as ‘Inactive’ from the other assay types. Because there were 
too many negative samples in the PubChem bioassays, we first collected only negative 
samples whose drug or target was included in the positive samples of the PubChem 
bioassays. Second, we selected as many random negative samples as positive DTIs from 
PubChem BioAssay. As a result, 18,228 positive and negative samples were built with 
21,907 drugs and 698 proteins. For the performance evaluation, we created three subsets of 
the PubChem bioassay independent dataset for humans, which consisted of only new 
compounds, new proteins, and new DTIs. We also collected samples from KinaseSARfari. 
KinaseSARfari consists of assays involving a compound that binds to a kinase domain. To 
obtain positive samples from KinaseSARfari, we considered each assay result with a 
dissociation constant of as positive [39], which is sufficiently small to be considered positive. 
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In contrast to the PubChem bioassays, the number of negative samples was similar to the 
number of positive samples in KinaseSARfari; therefore, we did not sample the negative 
samples. We collected 3,835 positive samples and 5,520 negative samples with 3,379 
compounds and 389 proteins. We confirmed that the training and the validation datasets were 
not biased toward a specific protein class. 
Drug feature representation 
In our model, we used the raw protein sequence as the input for the protein but did not use the 
raw SMILES string as the input for the drug. For the drug, we used the Morgan/Circular drug 
fingerprint, which analyzes molecules as a graph and retrieves substructures of molecular 
structures from subgraphs of the whole molecular graph [19]. Specifically, we used RDKit 
[40] to yield a Morgan/Circular fingerprint with a radius of 2 from a raw SMILES string. 
Finally, each drug can be represented as a binary vector with a length of 2048, whose indices 
indicate the existence of specific substructures.  
Selection of hyperparameters 
In our deep learning models, hyperparameters, such as the learning rate and window sizes 
that affect performance, are tuned during cross-validation. However, the hyperparameters 
should not be determined based on the performance of the subset of the training dataset 
because the negative datasets are randomly sampled. With the external validation dataset, we 
first determined the learning rate because a model with a high learning rate is unable to learn 
a pattern. After the learning rate was selected, we selected regularization parameters such as 
dropout ratio. Finally, we employed a grid-search method for optimization of the other 
hyperparameters. We identified hyperparameters that exhibited the best AUPR, which is an 
appropriate performance evaluation metric for the accuracy of classifying the positive 
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sample. The other descriptors to compare with our methods are numerical vectors, which do 
not have locality. Therefore, we put fully connected layers on the protein descriptors. We also 
employed a grid-search strategy while sustaining hyperparameters not related to model shape. 
When the AUPR is measured, the optimal threshold can be given by the EER [28]. 
EER = min
θ
(|1 − recall|  −  γ(1 − precision)|) 
where θ is the classification threshold and γ is the constant determining the cost ratio for 
misclassification from precision and recall, which is set at 2 in our model.  
Evaluation of performances 
To measure the prediction performance of our deep neural model based on the independent 
test dataset after the classification threshold was fixed, we obtained the following 
performance metrics: sensitivity (Sen), specificity (Spe), precision (Pre), accuracy (Acc), and 
the F1 measure (F1). 
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